Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: DNA antibody, Differential white blood cell count, Disturbance in attention, Electrophoresis protein, Fatigue
Clinical narrative: NOTICE:  I received two Moderna vaccinations.  This VAERS Form  includes both vaccines received.  I received the  first Moderna vaccination administered on 3/5/2021.  Adverse Events:  During April 2021 I started to experience headaches and pain in both temporal areas and frontal areas of the head.  The top of my head became very sensitive to the touch and very painful.   Throat became swollen and speech was somewhat impaired.  A pressure like feel was experienced behind the eyes causing some vision focus difficulty.  Increasing loss of clear thinking along with some fatigue through May/June/July time frame along with more difficultly concentrating.  Treatment:  Met with my family physician to discuss my symptoms and requested treatment on July 21, 2021.  A series of test were run to diagnose the problems I was having. Test results indicated a Sedimentation Rate >120 MM/HR (0-10 MM/HR normal range) indicating a very high level of inflammation.   I was immediately administered Prednisone of 20 mg daily to reduce inflammation.  I was also referred to a rheumatologist for further examination.  Met with rheumatologist on three occasions to date: 8/4/2021, 8/13/2021 and 9/13/2021.  Initially I was diagnosed with GCA and placed on 40 mg prednisone (July 31 thru Aug 14) to reduce inflammation to head area.  Also underwent temporal vascular biopsy on 9/9/2021 to confirm GCA but biopsy was negative.  The results of the biopsy is in question due to the use of prednisone which commenced on July 22, 2021?  Further testing on 8/5/2021 indicated Neutrophil Cytoplasmic Antibody (P ANCA POSITIVE) with value of >=1:320. On 8/13/2021 I was Diagnosed with P ANCA Positive Drug Induced Vasculitis.  A  prednisone reducing protocol was started on 8/15/2021 by 5 mg/week so as to monitor symptoms for change.  The prednisone has had a positive response to my Sedimentation Rates on 8/2/2021 of 115 MM/HR,  8/5/2021 of 59 MM/HR, and 9/7/2021 of 9 MM/HR (normal range being 0-10 MM/HR).  I am on standing test orders for the following tests:  CRP and ESR, cANCA and pANCA, Complement C3, Complement C4, and anti-MPO and anti-PR3.  Next scheduled testing date is 10/13/2021 two days prior to my next appointment with the rheumatologist on 10/15/2021.   Outcome to date:  Currently on prednisone dose of 20 mg/day and most head pain has been relieved.  I still have head fogginess and some difficulty concentrating.  Front lobe of head has a constant low level numbing pain that does not go away.  My next visit with rheumatologist is scheduled for 10/15/2021.  Plan is to monitor the Vasculitis with future P ANAC testing to see if it is temporary condition that hopefully will disappear over time?  In the mean time I do not plan on a COVID-19 booster given my current state of concern with the COVID-19 vaccine on my health  Further Actions:  Contacted Moderna company on 9/22/2021 to report my potential adverse reaction to their COVID-19 vaccine as described in the above VAERS.   CASE # MOD21-146318. There was a progressive worsening of these symptoms until I was administrated therapeutics by my first responder family health physician on 7/22/2021. This period extended for approximately 15 weeks after the last Moderna vaccination dated 4/2/2021.  The timing of these events is what caused me to initiate this submission of the VAERS.